The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine, but limited its use to older adults and people ...

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

After a six-week long delay, The Food and Drug Administration (FDA) has finally approved a more traditional protein-based covid vaccine produced by pharmaceutical giant Novavax.

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

The U.S. Food and Drug Administration approved Novavax’s Covid-19 vaccine, but limited its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.

The Novavax Covid-19 vaccine, which uses more traditional protein-based technology than the mRNA vaccines from ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

Kennedy Jr., has severely restricted the use of the NovavaxCOVID-19 vaccine. The vaccine will now only be available to ...

Heiko von der Leyen, a German physician and professor, has spent much of his life in the medical field, contributing to ...

The death of a young boy with Duchenne muscular dystrophy (DMD) who was treated with Pfizer’s experimental gene therapy in a phase 2 trial has prompted the company to pause dosing in another study.